Ligand Pharmaceuticals Incorporated LGND 深 沪
已收盘 08-21 16:00:00 美东时间
286.29
-1.100
-0.38%
华盛通- 最 高289.98
- 今 开288.09
- 成交量 15.25万股
- 最 低 285.21
- 昨 收 287.39
- 总市值 57.07亿
- 52周最高 326.63
- 市盈率 静 46.68
- 换手率 0.77%
- 52周最低 160.80
- 委 比 91.09%
- 总股本 1993.56万
- 历史最高 326.63
- 量 比 0.79
- 振 幅 1.66%
- 历史最低 -19.8529
- 每 手 1
- 风险率 43.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330
Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.
08-15 03:52
Regeneron, Tenet leads top healthcare companies with highest earnings beats
As corporate earnings season progresses, investors are tracking sector performance metrics to gauge underlying healthcare demand and corporate efficiency. For the healthcare sector, spanning critical ...
08-12 18:54
财报速睇 | Ligand Pharmaceuticals Incorporated 2026财年Q2营收0.64亿美元，同比增长33.7%；归母净利润0.49亿美元，同比增长900.8%
华盛资讯8月8日讯，Ligand Pharmaceuticals Incorporated公布2026财年Q2业绩，公司Q2营收0.64亿美元，同比增长33.7%，归母净利润0.49亿美元，同比增长900.8%。
08-08 04:22
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
财报速睇 | Ligand Pharmaceuticals Incorporated 2026财年Q2营收0.64亿美元，同比增长33.7%；归母净利润0.49亿美元，同比增长900.8%
华盛资讯8月6日讯，Ligand Pharmaceuticals Incorporated公布2026财年Q2业绩，公司Q2营收0.64亿美元，同比增长33.7%，归母净利润0.49亿美元，同比增长900.8%。
08-06 22:13
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326
Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.
08-03 22:23
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
Ligand Pharmaceuticals Incorporated will report its second quarter 2026 financial results on August 6, 2026, followed by a conference call at 8:30 a.m. Eastern time. The call will discuss the results and provide a business update. The conference call details include dial-in numbers for the U.S. and international participants, as well as a webcast link for live and replay access. Ligand, a leading royalty aggregator, manages a diversified portfoli...
07-23 11:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
